| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
38,769 |
33,102 |
$3.73M |
| S9083 |
Global fee urgent care centers |
20,821 |
17,358 |
$1.90M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
18,070 |
17,932 |
$1.73M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
14,457 |
13,460 |
$1.41M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
7,022 |
7,012 |
$696K |
| S9088 |
Services provided in an urgent care center (list in addition to code for service) |
6,075 |
5,352 |
$111K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
864 |
771 |
$72K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
11,180 |
10,513 |
$68K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
5,223 |
3,531 |
$36K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
271 |
271 |
$28K |
| 36415 |
Collection of venous blood by venipuncture |
2,997 |
2,930 |
$22K |
| 81025 |
|
2,294 |
2,234 |
$16K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
437 |
432 |
$15K |
| 81003 |
|
1,856 |
1,815 |
$10K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
4,140 |
4,046 |
$5K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
271 |
264 |
$3K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
703 |
685 |
$2K |
| 71046 |
Radiologic examination, chest; 2 views |
274 |
273 |
$2K |
| 81000 |
|
560 |
534 |
$2K |
| 93000 |
|
471 |
470 |
$1K |
| 87400 |
|
134 |
127 |
$1K |
| 99385 |
|
27 |
27 |
$966.46 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
100 |
100 |
$813.13 |
| 0012A |
|
33 |
33 |
$764.31 |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
36 |
34 |
$735.24 |
| 87807 |
|
439 |
436 |
$696.88 |
| 0011A |
|
32 |
32 |
$636.25 |
| 90686 |
|
76 |
76 |
$507.83 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
75 |
75 |
$409.61 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
29 |
29 |
$322.86 |
| 86580 |
|
84 |
81 |
$241.20 |
| 90656 |
|
43 |
43 |
$220.66 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
82 |
82 |
$204.80 |
| 73630 |
|
13 |
12 |
$181.09 |
| 73130 |
|
12 |
12 |
$116.78 |
| 81002 |
|
81 |
76 |
$108.04 |
| 86592 |
|
24 |
24 |
$87.96 |
| 73610 |
|
12 |
12 |
$85.94 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
32 |
30 |
$75.88 |
| 82962 |
|
58 |
57 |
$72.91 |
| 87340 |
|
32 |
32 |
$72.65 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
59 |
58 |
$69.36 |
| 87481 |
|
15 |
15 |
$49.10 |
| 86803 |
|
19 |
19 |
$35.81 |
| 99000 |
|
2,544 |
2,427 |
$4.52 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
62 |
62 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
124 |
106 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
73 |
65 |
$0.00 |